A detailed history of Cwm, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Cwm, LLC holds 65 shares of MDGL stock, worth $20,610. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65
Previous 103 36.89%
Holding current value
$20,610
Previous $29,000 51.72%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

SELL
$212.22 - $292.96 $8,064 - $11,132
-38 Reduced 36.89%
65 $14,000
Q2 2024

Jul 09, 2024

BUY
$193.33 - $291.99 $2,126 - $3,211
11 Added 11.96%
103 $29,000
Q1 2024

Apr 05, 2024

BUY
$171.37 - $283.23 $6,683 - $11,045
39 Added 73.58%
92 $25,000
Q4 2023

Feb 01, 2024

SELL
$120.4 - $237.13 $2,046 - $4,031
-17 Reduced 24.29%
53 $12,000
Q3 2023

Oct 11, 2023

SELL
$146.04 - $225.78 $146 - $225
-1 Reduced 1.41%
70 $10,000
Q2 2023

Aug 03, 2023

BUY
$203.88 - $312.0 $3,465 - $5,304
17 Added 31.48%
71 $16,000
Q1 2023

Apr 28, 2023

BUY
$231.06 - $307.08 $924 - $1,228
4 Added 8.0%
54 $13,000
Q2 2022

Jul 28, 2022

SELL
$58.04 - $100.2 $1,044 - $1,803
-18 Reduced 26.47%
50 $4,000
Q1 2022

Apr 21, 2022

BUY
$55.89 - $101.89 $670 - $1,222
12 Added 21.43%
68 $7,000
Q4 2021

Jan 31, 2022

BUY
$72.34 - $95.09 $3,182 - $4,183
44 Added 366.67%
56 $5,000
Q3 2020

Oct 19, 2020

BUY
$99.78 - $124.21 $1,197 - $1,490
12 New
12 $1,000
Q1 2019

Apr 22, 2019

SELL
$103.48 - $143.84 $310 - $431
-3 Closed
0 $0
Q4 2018

Jan 25, 2019

BUY
$94.77 - $215.54 $284 - $646
3 New
3 $0

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.42B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.